Skip to content

Sleep Disturbances and Chronic Widespread Pain

Prevalence of Sleep Disturbances in Individuals With Chronic Widespread Pain

Status
Suspended
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03908905
Acronym
POSEIDON
Enrollment
96
Registered
2019-04-09
Start date
2019-09-01
Completion date
2025-06-30
Last updated
2024-02-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Widespread Pain, Sleep Disturbance

Keywords

Pain, Sleep, Neuropsychology, Fatigue, Activity level, Attention, Executive function, Memory

Brief summary

Chronic widespread pain (CWP), defined as long-lasting pain in multiple body regions, has a prevalence of 10-14% in Europe and is associated with other physical symptoms such as fatigue and cognitive problems. Individuals with longstanding pain also have a high prevalence of sleep disturbances, and sleep problems can in itself lead to tiredness, lower neurocognitive function and higher pain ratings. However, studies of comorbid sleep problems for individuals with CWP are a lacking, and the primary aim for the present study is to assess the prevalence of sleep disturbances in individuals with CWP, and to see how this covariates with pain, fatigue, activity level, neurocognitive functioning, and biomarkers. As a secondary aim the study will assess a subgroup of the individuals, that has received multimodal pain management treatment, a second time after 6 months to analyze how the prevalence of sleep disturbances and other associated problems covaries over time.

Interventions

DIAGNOSTIC_TESTPolysomnography

Sleep screening, neurocognitive assessment, activity monitoring questionnaires, blood sample

Sponsors

Uppsala University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years

Inclusion criteria

* Chronic Widespread Pain

Exclusion criteria

* Other untreated and or serious psychiatric or somatic conditions

Design outcomes

Primary

MeasureTime frameDescription
Polysomnography6 monthsAssessment of objective sleep problems

Secondary

MeasureTime frameDescription
CANTAB6 monthsNeurocognitive screening
Actigraph6 monthsActivity level
Biomarkers6 months92-plex inflammatory panel
Pain level6 monthsThe Brief Pain Inventory - Short Form, BPI, a 9 item (0-10) self-administered questionnaire, assessing the severity of a patient's pain and the impact of this pain on the patient's daily functioning. Maximum total score possible is 90. Higher the score, greater the degree of disability.
Fatigue6 monthsFatigue severity scale, FSS, a 9 item self-administered questionnaire assessing severity of fatigue and how fatigue interferes with activity. Items are scored on a 7 point scale, minimum total score possible is 9 and maximum 63. Higher the score, greater the severity.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026